Resveratrol (Synonyms: 白藜芦醇; trans-Resveratrol; SRT501)

目录号: HY-16561 纯度: 99.94%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Resveratrol (trans-Resveratrol; SRT501) 是一种天然多酚，具有抗氧化，抗炎，保护心脏和抗癌的特性。它的靶点广泛，如 mTOR、JAK、β-amyloid、Adenylyl cyclase、IKKβ、DNA polymerase。Resveratrol 也是一种特异性的 SIRT1 活化剂。Resveratrol 是有效的孕烷 X 受体 (PXR) 抑制剂。Resveratrol 是一种 Nrf2 激活剂，在小鼠模型中可以改善衰老相关的进行性肾损伤。Resveratrol 作用于内皮细胞促进 NO 产生。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Resveratrol Chemical Structure

CAS No. : 501-36-0

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥550	In-stock
200 mg	￥500	In-stock
500 mg	￥1050	In-stock
1 g		询价
5 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Resveratrol:

MCE 顾客使用本产品发表的 99 篇科研文献

: Resveratrol purchased from MCE. Usage Cited in: Redox Biol. 2022 Jun;52:102310. [Abstract]; Primary cardiomyocytes are transfected with NC-siRNA or Sesn2-siRNA for 24 h, and then treated with DOX (1 μM) in the presence or absence of Resveratrol (RES) (20 μM) for 24 h. Representative images of DHE (red) staining and quantification of the corresponding fluorescence intensity in H9c2 cells.

: Resveratrol purchased from MCE. Usage Cited in: Redox Biol. 2022 Jun;52:102310. [Abstract]; Resveratrol (RES) (10 mg/kg/day; intraperitoneally injected every day for 5 weeks) administration recoveres DOX-reduced expression of SIRT1 in hearts of Sirt1flox/flox mice.

: Resveratrol purchased from MCE. Usage Cited in: Redox Biol. 2022 Jun;52:102310. [Abstract]; Primary cardiomyocytes are transfected with NC-siRNA or Sesn2-siRNA for 24 h, and then treated with DOX (1 μM) in the presence or absence of Resveratrol (RES) (20 μM) for 24 h. The protein expression of SIRT1, SESN2, P-AMPKα, AMPKα and cleaved caspase-3 was detected by western blot analysis with densitometric quantification of each group.

: Resveratrol purchased from MCE. Usage Cited in: PLoS Biol. 2022 Jun 30;20(6):e3001682. [Abstract]; Immunostaining and brightfield of embryos either untreated or treated with solvent or with Resveratrol (1 μM).

: Resveratrol purchased from MCE. Usage Cited in: Biomed Pharmacother. 2022 Jun;150:113071.; EX527 antagonizes the protective effect of NRH on Kanamycin-induced hair-cell loss by inhibition of SIRT1, while Resveratrol (RSV; 10 μM) alleviates hair-cell damage caused by EX527.

: Resveratrol purchased from MCE. Usage Cited in: Cells. 2022 Jul 29;11(15):2331.; The depletion of HSF1 significantly decreased the reactivation efficiencies of Resveratrol.

: Resveratrol purchased from MCE. Usage Cited in: Cell Prolif. 2021 Mar;54(3):e12991. [Abstract]; Representative immunoblots of Ac p53 K381, total p53, progerin, Lamin A/C and Lamin B1 of primary HSECs on Day 2 in four groups (CTR, H2O2, H2O2 + Resveratrol, Resveratrol (1 μM; 2 days)).

: Resveratrol purchased from MCE. Usage Cited in: Cell Death Dis. 2021 Nov 29;12(12):1115. [Abstract]; Western blot and quantification for MICU3 in C2C12 cells treated with d-gal and Resveratrol (50 μM).

: Resveratrol purchased from MCE. Usage Cited in: Free Radic Biol Med. 2021 Nov 20;176:228-240. [Abstract]; Representative images of Rhodamine and DHE of treated BMSCs after indicated treatment.

: Resveratrol purchased from MCE. Usage Cited in: Free Radic Biol Med. 2021 Nov 20;176:228-240. [Abstract]; The expression levels of SIRT3, RUNX2, OCN in BMSCs after indicated treatment are analyzed by western blot.

: Resveratrol purchased from MCE. Usage Cited in: ACS Infect Dis. 2021 Apr 9;7(4):777-789. [Abstract]; Effects of Resveratrol on meningitic E. coli-induced ERK1/2 activation as well as VEGFA upregulation in hBMECs. By pretreatment with Resveratrol, the phosphorylation of ERK1/2 induced by meningitic E. coli in hBMECs is significantly reduced. Similarly, the upregulation of VEGFA also decreased considerably in a dose-dependent manner in resveratrol-treated hBMECs.

: Resveratrol purchased from MCE. Usage Cited in: Acta Pharmacol Sin. 2021 Feb;42(2):242-251. [Abstract]; Resveratrol (50 mg/kg; i.p.; for 2 weeks) has no effect on body weight and kidney index in mice, but it significantly reduces FBG, BUN, and CR.

: Resveratrol purchased from MCE. Usage Cited in: Acta Pharmacol Sin. 2021 Feb;42(2):242-251. [Abstract]; Western blotting demonstrates that Resveratrol (50 mg/kg; i.p.; for 2 weeks) increases the expression of E-Ca and ZO-1 and decreases the expression of α-SMA, vimentin, snail, and twist.

: Resveratrol purchased from MCE. Usage Cited in: Cell Death Dis. 2018 Aug 28;9(9):847. [Abstract]; HIPK2 expression is upregulated by treatments with 5 μM Resveratrol, 30 μM Aspirin, 10 μM Vitamin E, and 15 μM Ursolic acid for another 16 h after the LPS treatment, as analysed by western blotting.

: Resveratrol purchased from MCE. Usage Cited in: J Agric Food Chem. 2017 Jun 7;65(22):4384-4394. [Abstract]; Resveratrol activates the HSF1 signaling pathway. J-Lat A2 cells are treated with various concentrations of Resveratrol or Carfilzomib (50 nM) for 48 h. Then the cells are lysed and Ser320 phosphorylated HSF1 and total HSF1 are detected by Western blot with corresponding antibodies.

: Resveratrol purchased from MCE. Usage Cited in: Chinese Journal of Cell Biology. 2015, 37(11):1522-1527.; Effect of Resveratrol on SIRT1 expression in HK-2 cells.

Resveratrol 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 IKK 亚型特异性产品:

查看所有亚型

IKK-α IKK-β IKK IKKε TBK1

查看 Sirtuin 亚型特异性产品:

查看所有亚型

Sirtuin SIRT1 SIRT2 SIRT3 SIRT6 SIRT5 SIRT7

查看 Antibiotic 亚型特异性产品:

查看所有亚型

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator^[1]^[2]^[3]^[4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor^[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model^[6]. Resveratrol increases production of NO in endothelial cells^[7].

IC₅₀ & Target^[1]

Adenylyl cyclase

0.8 nM (IC₅₀)

IKKβ

1 μM (IC₅₀)

DNA polymerase α

3.3 μM (IC₅₀)

DNA polymerase δ

5 μM (IC₅₀)

Autophagy

Mitophagy

Sirtuin

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
3T3-L1	IC₅₀	31.4 μM Compound: resveratrol	Antiadipogenic activity against mouse 3T3L1 cells assessed as inhibition of differentiation after 7 days by oil-red O staining Antiadipogenic activity against mouse 3T3L1 cells assessed as inhibition of differentiation after 7 days by oil-red O staining	[PMID: 19757853]
518A2	IC₅₀	> 30 μM Compound: 22	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 22749392]
A253 cell line	IC₅₀	> 30 μM Compound: 22	Cytotoxicity against human A253 cells after 96 hrs by SRB assay Cytotoxicity against human A253 cells after 96 hrs by SRB assay	[PMID: 22749392]
A2780	IC₅₀	> 30 μM Compound: 22	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 22749392]
A2780	IC₅₀	48 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human A2780 cells assessed as cell growth inhibition incubated for 24 hrs days by MTT assay Anticancer activity against human A2780 cells assessed as cell growth inhibition incubated for 24 hrs days by MTT assay	[PMID: 32485531]
A2780	IC₅₀	65 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human A2780 cells assessed as cell growth inhibition by LDH release assay Anticancer activity against human A2780 cells assessed as cell growth inhibition by LDH release assay	[PMID: 32485531]
A2780	IC₅₀	74 μM Compound: 5	Antiproliferative activity against human A2780 cells after 2 days by Alamar Blue assay Antiproliferative activity against human A2780 cells after 2 days by Alamar Blue assay	[PMID: 24239390]
A-431	IC₅₀	49.4 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human A-431 cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay Anticancer activity against human A-431 cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay	[PMID: 32485531]
A549	IC₅₀	> 100 μM Compound: Resveratrol	Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25817772]
A549	IC₅₀	> 30 μM Compound: 22	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 22749392]
A549	IC₅₀	10.5 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32485531]
A549	IC₅₀	119.6 μM Compound: Res, Resveratrol	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 21920747]
A549	IC₅₀	16 μM Compound: Resv	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
A549	IC₅₀	30.4 μg/mL Compound: RES	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 21440448]
A549	IC₅₀	44.7 pM Compound: 1, RSV, Resveratrol	Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 21851083]
A549	CC₅₀	52.6 μM Compound: Resveratrol	Cytotoxicity against human A549 cells assessed as reduction in cell viability by Alamar blue assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by Alamar blue assay	[PMID: 32652408]
A549	IC₅₀	66.25 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32485531]
ASPC1	IC₅₀	24.96 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human ASPC1 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Anticancer activity against human ASPC1 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32485531]
B16	IC₅₀	14.35 μg/mL Compound: Resveratrol	Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 18586355]
B16-F10	IC₅₀	> 200 μM Compound: 1, Resveratrol	Cytotoxicity against mouse B16F10 cells assessed as suppression of cell viability after 72 hrs Cytotoxicity against mouse B16F10 cells assessed as suppression of cell viability after 72 hrs	[PMID: 22189272]
B16-F10	IC₅₀	37.3 μg/mL Compound: RES	Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay	[PMID: 21440448]
Bel-7402	IC₅₀	139.03 μM Compound: Res	Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27887843]
Bel-7402	IC₅₀	50.7 μM Compound: Resveratrol	Antiproliferative activity against human Bel7402 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human Bel7402 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25817772]
BV-2	IC₅₀	10.32 μM Compound: Res	Anti-neuroinflammation in mouse BV2 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS addition measured after 24 hrs by Griess reagent based assay Anti-neuroinflammation in mouse BV2 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS addition measured after 24 hrs by Griess reagent based assay	[PMID: 33017743]
BV-2	IC₅₀	10.99 μM Compound: Resveratrol	Inhibition of NO production in LPS-induced mouse BV-2 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA Inhibition of NO production in LPS-induced mouse BV-2 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 34752955]
BV-2	IC₅₀	11.1 μM Compound: Res	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 30 mins followed by LPS-stimulation for 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 30 mins followed by LPS-stimulation for 24 hrs by Griess assay	[PMID: 30771601]
BV-2	IC₅₀	11.1 μM Compound: Resveratrol	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by Griess assay	[PMID: 29499485]
BV-2	IC₅₀	18.66 μM Compound: 30	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay	[PMID: 28911817]
BV-2	IC₅₀	8.7 μM Compound: Resveratrol	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced IL-1beta production after 24 hrs by ELISA Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced IL-1beta production after 24 hrs by ELISA	[PMID: 29499485]
BV-2	IC₅₀	9.5 μM Compound: Resveratrol	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced TNFalpha production after 24 hrs by ELISA Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced TNFalpha production after 24 hrs by ELISA	[PMID: 29499485]
BXPC-3	IC₅₀	14 μM Compound: Resv	Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
BXPC-3	IC₅₀	27.98 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human BXPC-3 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Anticancer activity against human BXPC-3 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32485531]
BXPC-3	GI₅₀	3.3 μg/mL Compound: 1a	Growth inhibition of human BxPC3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human BxPC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 19719153]
BXPC-3	GI₅₀	3.3 μg/mL Compound: E-3	Cytotoxicity against human BxPC3 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human BxPC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
C8166	CC₅₀	35.57 μg/mL Compound: Resveratrol	Cytotoxicity against human C8166 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human C8166 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32652408]
Caco-2	IC₅₀	190.2 μM Compound: RSV; 1, Trans-RSV	Anti cancer activity against human Caco-2 cell assessed as cell growth inhibition incubated for 48 hrs by Brdu assay Anti cancer activity against human Caco-2 cell assessed as cell growth inhibition incubated for 48 hrs by Brdu assay	[PMID: 32485531]
Caco-2	IC₅₀	24.35 μM Compound: 17, Resveratrol	Cytotoxicity against human Caco-2 cells after 3 days by [3H]thymidine incorporation assay Cytotoxicity against human Caco-2 cells after 3 days by [3H]thymidine incorporation assay	[PMID: 20627379]
Capan-2	IC₅₀	26.49 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human Capan-2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Anticancer activity against human Capan-2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32485531]
CCRF-CEM	IC₅₀	0.9 μM Compound: Resveratrol	Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay	[PMID: 36691388]
CCRF-CEM	IC₅₀	5.91 μg/mL Compound: Resveratrol	Cytotoxicity against human CEM cells after 72 hrs by MTT assay Cytotoxicity against human CEM cells after 72 hrs by MTT assay	[PMID: 18586355]
CNE	IC₅₀	67.62 μM Compound: 1, resveratrol,(Res)	Antiproliferative activity against human CNE1 cells after 72 hrs by MTT assay Antiproliferative activity against human CNE1 cells after 72 hrs by MTT assay	[PMID: 18952444]
CNE-2	IC₅₀	52.28 μM Compound: 1, resveratrol,(Res)	Antiproliferative activity against human CNE2 cells after 72 hrs by MTT assay Antiproliferative activity against human CNE2 cells after 72 hrs by MTT assay	[PMID: 18952444]
COLO 201	IC₅₀	37 μM Compound: Resv	Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
COLO 205	IC₅₀	23.5 μM Compound: Resveratrol	Antiproliferative activity against human COLO205 cells by MTT assay Antiproliferative activity against human COLO205 cells by MTT assay	[PMID: 25455486]
DLD-1	IC₅₀	> 30 μM Compound: 22	Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay	[PMID: 22749392]
DLKP cell line	IC₅₀	10 μM Compound: 1	Antiproliferative activity against MRP1-expressing human DLKP cells after 5 days by acid phosphatase assay Antiproliferative activity against MRP1-expressing human DLKP cells after 5 days by acid phosphatase assay	[PMID: 19481462]
DU-145	GI₅₀	3.5 μg/mL Compound: 1a	Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay	[PMID: 19719153]
DU-145	GI₅₀	3.5 μg/mL Compound: E-3	Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
Fibroblast	IC₅₀	218 μM Compound: Resveratrol	Cytotoxicity against fibroblast (unknown origin) cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay Cytotoxicity against fibroblast (unknown origin) cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay	[PMID: 36691388]
HaCaT	IC₅₀	18.31 μM Compound: Resveratrol	Antiinflammatory activity against human HaCaT cells assessed as inhibition of UVB irradiation-induced PGE2 production measured after 2 hrs by ELISA Antiinflammatory activity against human HaCaT cells assessed as inhibition of UVB irradiation-induced PGE2 production measured after 2 hrs by ELISA	[PMID: 35172097]
HaCaT	IC₅₀	35.1 μM Compound: Trans-Resveratrol	Inhibition of ultraviolet B-irradiation upregulated of prostaglandin E2 production in human HaCaT cells measured after 2 hrs by ELISA Inhibition of ultraviolet B-irradiation upregulated of prostaglandin E2 production in human HaCaT cells measured after 2 hrs by ELISA	[PMID: 34463498]
HaCaT	IC₅₀	85.2 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HaCaT cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay Anticancer activity against human HaCaT cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay	[PMID: 32485531]
HCT-116	IC₅₀	> 60 μM Compound: 1	Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 26204233]
HCT-116	IC₅₀	31 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 5 days by SRB assay Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 5 days by SRB assay	[PMID: 32485531]
HCT-116	IC₅₀	62.61 μM Compound: Res	Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27887843]
HCT-8	IC₅₀	5.82 μg/mL Compound: Resveratrol	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 18586355]
HEK293	EC₅₀	> 30 μM Compound: 1	Agonist activity at human TRPA1 expressed in HEK293 cells assessed as induction of calcium influx at 30 uM after 6 mins by Fluo-4 dye-based assay Agonist activity at human TRPA1 expressed in HEK293 cells assessed as induction of calcium influx at 30 uM after 6 mins by Fluo-4 dye-based assay	[PMID: 28576617]
HEK293	IC₅₀	> 30 μM Compound: 1	Inhibition of human TRPA1 expressed in HEK293 cells assessed as decrease in AITC-induced calcium influx preincubated for 6 mins followed by AITC addition measured for 1 min by Fluo-4 dye-based assay Inhibition of human TRPA1 expressed in HEK293 cells assessed as decrease in AITC-induced calcium influx preincubated for 6 mins followed by AITC addition measured for 1 min by Fluo-4 dye-based assay	[PMID: 28576617]
HEK293	IC₅₀	0.173 μM Compound: 1, Resveratrol	Inhibition of TNF-alpha-induced NF-kappaB activity expressed in HEK293 cells after 48 hrs by luciferase reporter gene assay Inhibition of TNF-alpha-induced NF-kappaB activity expressed in HEK293 cells after 48 hrs by luciferase reporter gene assay	[PMID: 20527891]
HEK293	IC₅₀	0.75 μM Compound: 1	Inhibition of human TRPA1 expressed in HEK293 cells assessed as decrease in AITC-induced current response by whole cell patch clamp method Inhibition of human TRPA1 expressed in HEK293 cells assessed as decrease in AITC-induced current response by whole cell patch clamp method	[PMID: 28576617]
HEK293	IC₅₀	0.98 μM Compound: 1	Inhibition of TNFalpha-induced NF-kappaB activity expressed in HEK293 cells by luciferase reporter gene assay Inhibition of TNFalpha-induced NF-kappaB activity expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 23142320]
HEK293	IC₅₀	0.98 μM Compound: 1	Inhibition of TNF-alpha activated NF-kappaB expressed in HEK293 cells by luciferase reporter gene assay Inhibition of TNF-alpha activated NF-kappaB expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 22386564]
HEK293	IC₅₀	0.98 μM Compound: trans-Resveratrol	Inhibition of TNFalpha-activated NF-kappaB expressed in HEK293 cells by luciferase reporter gene assay Inhibition of TNFalpha-activated NF-kappaB expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 22115839]
HEK293	IC₅₀	12 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HEK293 cells assessed as cell growth inhibition incubated for 3 days by MTT assay Anticancer activity against human HEK293 cells assessed as cell growth inhibition incubated for 3 days by MTT assay	[PMID: 32485531]
HEK293	IC₅₀	16.1 μM Compound: resveratrol	Inhibition of TNFalpha induced NF-kappaB activation in human 293 cells after 24 hrs by luciferase reporter gene assay Inhibition of TNFalpha induced NF-kappaB activation in human 293 cells after 24 hrs by luciferase reporter gene assay	[PMID: 18487053]
HEK293	IC₅₀	17 μM Compound: RTV	Growth inhibition of HEK293 cells after 2 days by MTT assay Growth inhibition of HEK293 cells after 2 days by MTT assay	[PMID: 28408224]
HEK293	IC₅₀	2.5 μM Compound: Resveratrol	Inhibition of TNF-alpha-induced NF-kappaB activity in HEK293 cells after 6 hrs by luciferase reporter gene assay Inhibition of TNF-alpha-induced NF-kappaB activity in HEK293 cells after 6 hrs by luciferase reporter gene assay	[PMID: 24992702]
HEK293	IC₅₀	31 μM Compound: Resveratrol	Cytotoxicity against HEK293 cells after 3 days by MTT assay Cytotoxicity against HEK293 cells after 3 days by MTT assay	10.1039/C5MD00197H
HEK293	IC₅₀	7.1 μg/mL Compound: Resv.	Cytotoxicity against HEK293 cells assessed inhibition of cell proliferation after 2 days by MTT assay Cytotoxicity against HEK293 cells assessed inhibition of cell proliferation after 2 days by MTT assay	[PMID: 26402726]
HEK-293T	CC₅₀	22.75 μM Compound: Res	Cytotoxicity against HEK293T cells after 24 hrs by MTT assay Cytotoxicity against HEK293T cells after 24 hrs by MTT assay	[PMID: 29172079]
HeLa	IC₅₀	10.5 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Anticancer activity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32485531]
HeLa	IC₅₀	120.27 μM Compound: Res	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27887843]
HeLa	IC₅₀	152.4 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32485531]
HeLa	IC₅₀	22.5 pM Compound: 1, RSV, Resveratrol	Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 21851083]
HeLa	IC₅₀	47.9 μM Compound: Resveratrol	Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25817772]
HeLa	IC₅₀	58.86 μM Compound: Resveratrol	Antitumor activity against human HeLa cells assessed as growth inhibition measured after 48 hrs by MTT assay Antitumor activity against human HeLa cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 23313635]
HeLa	IC₅₀	98.17 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Anticancer activity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32485531]
HepG2	IC₅₀	> 100 μM Compound: Resveratrol	Antitumor activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay Antitumor activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 23313635]
HepG2	IC₅₀	110.7 μM Compound: RSV; 1, Trans-RSV	Anti cancer activity against human HepG2 cell assessed as cell growth inhibition incubated for 48 hrs by Brdu assay Anti cancer activity against human HepG2 cell assessed as cell growth inhibition incubated for 48 hrs by Brdu assay	[PMID: 32485531]
HepG2	IC₅₀	354.8 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 3 days by MTT assay Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 3 days by MTT assay	[PMID: 32485531]
HepG2	IC₅₀	38.9 μg/mL Compound: RES	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 21440448]
HepG2	EC₅₀	5.4 μM Compound: Resveratrol	Activation of Nrf2 (unknown origin) expressed in human HepG2 cells after 5 hrs by ARE-driven luciferase reporter gene assay Activation of Nrf2 (unknown origin) expressed in human HepG2 cells after 5 hrs by ARE-driven luciferase reporter gene assay	[PMID: 28126440]
HepG2	IC₅₀	50 μM Compound: resveratrol	Cytotoxicity against human HepG2 cells after 48 hrs by acid phosphatase method Cytotoxicity against human HepG2 cells after 48 hrs by acid phosphatase method	[PMID: 16252924]
HepG2	IC₅₀	54.9 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32485531]
HepG2	IC₅₀	79.6 μM Compound: Resveratrol	Growth inhibition of human HepG2 cells after 72 hrs by sulforhodamine B assay Growth inhibition of human HepG2 cells after 72 hrs by sulforhodamine B assay	[PMID: 20346660]
HepG2	IC₅₀	80.3 μM Compound: RSV, Resveratrol	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 22326393]
HL-60	IC₅₀	2.45 μg/mL Compound: Resveratrol	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 18586355]
HL-60	IC₅₀	31.8 μM Compound: 4, (E)-resveratrol	Cytotoxicity against human HL60 cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human HL60 cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
HL-60	IC₅₀	36.3 μM Compound: resveratrol	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 19251420]
HL-60	IC₅₀	64.1 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HL-60 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Anticancer activity against human HL-60 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32485531]
HOS-TE85	IC₅₀	20.57 μM Compound: 29	Cytotoxicity against human MNNG/HOS cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against human MNNG/HOS cells incubated for 48 hrs by CCK-8 assay	[PMID: 33325699]
HT-144	IC₅₀	40 μM Compound: 1	Antiproliferative activity against human HT144 cells after 5 days by acid phosphatase assay Antiproliferative activity against human HT144 cells after 5 days by acid phosphatase assay	[PMID: 19481462]
HT-22	EC₅₀	4667 nM Compound: Resveratrol	Neuroprotective activity in mouse HT22 cells assessed as protection against glutamate-induced oxytosis after 24 hrs by MTT assay Neuroprotective activity in mouse HT22 cells assessed as protection against glutamate-induced oxytosis after 24 hrs by MTT assay	[PMID: 21129978]
HT-29	IC₅₀	> 100 μM Compound: RES	Growth inhibition of human HT-29 cells after 48 hrs by MTT assay Growth inhibition of human HT-29 cells after 48 hrs by MTT assay	[PMID: 27783972]
HT-29	IC₅₀	> 60 μM Compound: 1	Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 26204233]
HT-29	IC₅₀	110 μM Compound: Resveratrol	Antiproliferative activity against human HT-29 cells after 3 days by MTT assay Antiproliferative activity against human HT-29 cells after 3 days by MTT assay	[PMID: 23623255]
HT-29	IC₅₀	1115.9 μM Compound: RSV; 1, Trans-RSV	Anti cancer activity against human HT-29 cell assessed as cell growth inhibition incubated for 48 hrs by Brdu assay Anti cancer activity against human HT-29 cell assessed as cell growth inhibition incubated for 48 hrs by Brdu assay	[PMID: 32485531]
HT-29	IC₅₀	120 μM Compound: Resveratrol	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay	[PMID: 36691388]
HT-29	IC₅₀	130 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32485531]
HT-29	IC₅₀	137 μM Compound: RTV	Growth inhibition of human HT-29 cells after 2 days by MTT assay Growth inhibition of human HT-29 cells after 2 days by MTT assay	[PMID: 28408224]
HT-29	IC₅₀	150 μM Compound: Resveratrol	Cytotoxicity against human HT-29 cells after 3 days by MTT assay Cytotoxicity against human HT-29 cells after 3 days by MTT assay	10.1039/C5MD00197H
HT-29	IC₅₀	27 μM Compound: Resv	Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
HT-29	IC₅₀	34.1 μg/mL Compound: Resv.	Cytotoxicity against human HT-29 cells assessed inhibition of cell proliferation after 2 days by MTT assay Cytotoxicity against human HT-29 cells assessed inhibition of cell proliferation after 2 days by MTT assay	[PMID: 26402726]
HT-29	IC₅₀	45.3 μM Compound: 17, Resveratrol	Cytotoxicity against human HT-29 cells after 3 days by [3H]thymidine incorporation assay Cytotoxicity against human HT-29 cells after 3 days by [3H]thymidine incorporation assay	[PMID: 20627379]
HT-29	IC₅₀	70 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 3 days by MTT assay Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 3 days by MTT assay	[PMID: 32485531]
HT-29	IC₅₀	87.2 μM Compound: Resveratrol	Antiproliferative activity against human HT-29 cells by MTT assay Antiproliferative activity against human HT-29 cells by MTT assay	[PMID: 25455486]
Huh-7	IC₅₀	10.6 μM Compound: Resveratrol	Cytotoxicity against human Huh7.5.1 cells after 72 hrs Cytotoxicity against human Huh7.5.1 cells after 72 hrs	[PMID: 23673225]
J774	IC₅₀	12.15 μM Compound: 3	Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 29726680]
J774	IC₅₀	13.6 μM Compound: 3	Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced MCP1 expression after 24 hrs by ELISA Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced MCP1 expression after 24 hrs by ELISA	[PMID: 29726680]
J774	IC₅₀	6.8 μM Compound: 3	Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced IL6 expression after 24 hrs by ELISA Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced IL6 expression after 24 hrs by ELISA	[PMID: 29726680]
K562	IC₅₀	9.62 μg/mL Compound: Resveratrol	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 18586355]
KB	IC₅₀	82.8 μM Compound: 1, RES, resveratrol	Cytotoxicity against human KB cells after 48 hrs Cytotoxicity against human KB cells after 48 hrs	[PMID: 17000031]
KM-20L2	GI₅₀	13.1 μg/mL Compound: 1a	Growth inhibition of human KM20L2 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human KM20L2 cells after 48 hrs by sulforhodamine B assay	[PMID: 19719153]
KM-20L2	GI₅₀	13.1 μg/mL Compound: E-3	Cytotoxicity against human KM20L2 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human KM20L2 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
L02	IC₅₀	98.6 μM Compound: Res	Cytotoxicity against human L02 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human L02 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27887843]
LLC-PK1	IC₅₀	52.5 μM Compound: 4, (E)-resveratrol	Cytotoxicity against pig LLC-PK1 cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against pig LLC-PK1 cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
LN-229	IC₅₀	11 μM Compound: Resv	Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
LoVo	IC₅₀	55 μM Compound: 56	Antiproliferative activity against human LoVo cells assessed as decrease in cell viability by MTT assay Antiproliferative activity against human LoVo cells assessed as decrease in cell viability by MTT assay	[PMID: 33445154]
MCF-10A	IC₅₀	> 100 μM Compound: RSV; 1, Trans-RSV	Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32485531]
MCF-12A	IC₅₀	93.5 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human MCF-12A cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay Anticancer activity against human MCF-12A cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay	[PMID: 32485531]
MCF7	IC₅₀	> 100 μM Compound: Resveratrol	Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25817772]
MCF7	IC₅₀	> 100 μM Compound: Resveratrol	Antitumor activity against human MCF7 cells assessed as growth inhibition measured after 48 hrs by MTT assay Antitumor activity against human MCF7 cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 23313635]
MCF7	IC₅₀	> 30 μM Compound: 22	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 22749392]
MCF7	IC₅₀	> 30 μM Compound: resveratrol	Cytotoxicity against human MCF7 cells after 72 hrs Cytotoxicity against human MCF7 cells after 72 hrs	[PMID: 10075742]
MCF7	IC₅₀	100 μM Compound: resveratrol	Cytotoxicity against human MCF7 cells after 48 hrs by acid phosphatase method Cytotoxicity against human MCF7 cells after 48 hrs by acid phosphatase method	[PMID: 16252924]
MCF7	IC₅₀	127 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 3 days by MTT assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 3 days by MTT assay	[PMID: 32485531]
MCF7	IC₅₀	135 μM Compound: Resveratrol	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay	[PMID: 36691388]
MCF7	IC₅₀	16.1 μg/mL Compound: Resv.	Cytotoxicity against human MCF7 cells assessed inhibition of cell proliferation after 2 days by MTT assay Cytotoxicity against human MCF7 cells assessed inhibition of cell proliferation after 2 days by MTT assay	[PMID: 26402726]
MCF7	IC₅₀	19 μM Compound: resveratrol	Inhibition of phorbol ester-induced ornithine decarboxylase in human MCF7 cells after 6 hrs Inhibition of phorbol ester-induced ornithine decarboxylase in human MCF7 cells after 6 hrs	[PMID: 10075742]
MCF7	IC₅₀	22.9 μM Compound: RES	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30053783]
MCF7	IC₅₀	24.6 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human MCF7 cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay	[PMID: 32485531]
MCF7	IC₅₀	25.4 μM Compound: RES	Antiproliferative activity against human MCF7 cells after 72 hrs in presence of OBHS by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs in presence of OBHS by MTT assay	[PMID: 30053783]
MCF7	IC₅₀	28.07 μM Compound: RSV, resveratrol	Cytotoxicity against human estrogen receptor positive MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human estrogen receptor positive MCF7 cells after 72 hrs by MTT assay	[PMID: 23860590]
MCF7	GI₅₀	3.9 μg/mL Compound: 1a	Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 19719153]
MCF7	GI₅₀	3.9 μg/mL Compound: E-3	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
MCF7	IC₅₀	34 μM Compound: RTV	Growth inhibition of human MCF7 cells after 2 days by MTT assay Growth inhibition of human MCF7 cells after 2 days by MTT assay	[PMID: 28408224]
MCF7	IC₅₀	40.49 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTS assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTS assay	[PMID: 32485531]
MCF7	IC₅₀	61.71 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs in presence of Curcumin by MTS assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs in presence of Curcumin by MTS assay	[PMID: 32485531]
MCF7	IC₅₀	62 μM Compound: Resveratrol	Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 26854376]
MCF7	IC₅₀	68.3 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human MCF7 cells assessed as cell growth inhibition by CyQuant assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition by CyQuant assay	[PMID: 32485531]
MCF7	IC₅₀	71 μM Compound: Resveratrol	Cytotoxicity against human MCF7 cells after 3 days by MTT assay Cytotoxicity against human MCF7 cells after 3 days by MTT assay	10.1039/C5MD00197H
MCF7	IC₅₀	79.1 pM Compound: 1, RSV, Resveratrol	Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 21851083]
MCF7	IC₅₀	80 μM Compound: Resveratrol	Antitumor activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antitumor activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32942072]
MCF7	IC₅₀	85 μM Compound: Resveratrol	Inhibition of telomerase extracted from human MCF7 cells after 24 to 48 hrs by TRAP assay Inhibition of telomerase extracted from human MCF7 cells after 24 to 48 hrs by TRAP assay	10.1039/C0MD00241K
MCF7	IC₅₀	87.6 μM Compound: 1	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 22386564]
MCF7	IC₅₀	88.2 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32485531]
MDA-MB-231	IC₅₀	> 100 μM Compound: RES	Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 27783972]
MDA-MB-231	IC₅₀	129.9 μM Compound: resveratrol	Antiproliferative activity human MDA-MB-231 cells assessed as cell survival after 48 hrs by MTT assay Antiproliferative activity human MDA-MB-231 cells assessed as cell survival after 48 hrs by MTT assay	[PMID: 26344592]
MDA-MB-231	IC₅₀	15 μM Compound: Resv	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
MDA-MB-231	IC₅₀	20.5 μM Compound: Resveratrol	Antitumor activity against human MDA-MB-231 cells after 6 days by SRB assay Antitumor activity against human MDA-MB-231 cells after 6 days by SRB assay	[PMID: 20728369]
MDA-MB-231	IC₅₀	40 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition by CyQuant assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition by CyQuant assay	[PMID: 32485531]
MDA-MB-231	IC₅₀	57 μM Compound: Resveratrol	Cytotoxicity against human MDA-MB-231 cells after 96 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 96 hrs by MTT assay	[PMID: 26854376]
MDA-MB-231	IC₅₀	66 μM Compound: Resveratrol	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 23273518]
MDA-MB-231	IC₅₀	90.6 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32485531]
MDA-MB-231	IC₅₀	98.84 μM Compound: Resveratrol	Antiproliferative activity against human MDA-MB-231 cells measured after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 24 hrs by MTT assay	[PMID: 34605238]
MDA-MB-435	IC₅₀	13.81 μg/mL Compound: Resveratrol	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 18586355]
MDA-MB-468	IC₅₀	45.2 μM Compound: Resveratrol	Antiproliferative activity against human MDA468 cells by MTT assay Antiproliferative activity against human MDA468 cells by MTT assay	[PMID: 25455486]
MDA-MB-468	IC₅₀	58 μM Compound: Resveratrol	Cytotoxicity against human MDA-MB-468 cells after 96 hrs by MTT assay Cytotoxicity against human MDA-MB-468 cells after 96 hrs by MTT assay	[PMID: 26854376]
MG-63	IC₅₀	28.58 μM Compound: 29	Cytotoxicity against human MG-63 cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against human MG-63 cells incubated for 48 hrs by CCK-8 assay	[PMID: 33325699]
MGC-803	IC₅₀	42 μM Compound: Resveratrol	Antiproliferative activity against human MGC803 cells by MTT assay Antiproliferative activity against human MGC803 cells by MTT assay	[PMID: 25455486]
Microglia	IC₅₀	11.5 μM Compound: resveratrol	Inhibition of LPS-stimulated NO release in rat cortical microglial cells assessed as nitrite accumulation after 48 hrs Inhibition of LPS-stimulated NO release in rat cortical microglial cells assessed as nitrite accumulation after 48 hrs	[PMID: 18588343]
MRC5	IC₅₀	56.6 μM Compound: 1; RES	Cytotoxicity against human MRC5 cells assessed as cellular metabolism incubated for 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as cellular metabolism incubated for 72 hrs by MTT assay	[PMID: 35621995]
NCI-H460	IC₅₀	12 μM Compound: Resv	Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
NCI-H460	IC₅₀	12.9 μM Compound: 2	Antiproliferative activity against human H460 cells after 72 hrs Antiproliferative activity against human H460 cells after 72 hrs	[PMID: 20409723]
NCI-H460	GI₅₀	3.6 μg/mL Compound: 1a	Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 19719153]
NCI-H460	GI₅₀	3.6 μg/mL Compound: E-3	Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
NCI-H460	IC₅₀	58 μM Compound: Resveratrol	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay	[PMID: 36691388]
NIH3T3	IC₅₀	> 20 μM Compound: RSV; 1, Trans-RSV	Cytotoxicity against mouse NIH3T3 cells assessed as cell growth inhibition by CyQuant assay Cytotoxicity against mouse NIH3T3 cells assessed as cell growth inhibition by CyQuant assay	[PMID: 32485531]
NIH3T3	IC₅₀	> 24.2 μM Compound: 1, 17 trans-resveratrol	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B colorimetric assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B colorimetric assay	[PMID: 21803587]
NIH3T3	IC₅₀	24.22 μM Compound: 22	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 22749392]
OVCAR-3	IC₅₀	480 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition incubated for 24 hrs days by MTT assay Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition incubated for 24 hrs days by MTT assay	[PMID: 32485531]
OVCAR-3	IC₅₀	525 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition by LDH release assay Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition by LDH release assay	[PMID: 32485531]
P388	ED₅₀	4.49 μg/mL Compound: E-3	Cytotoxicity against mouse P388 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against mouse P388 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
PANC-1	IC₅₀	39 μM Compound: Resv	Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
PANC-1	IC₅₀	70 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human PANC-1 cells assessed as cell growth inhibition by CyQuant assay Anticancer activity against human PANC-1 cells assessed as cell growth inhibition by CyQuant assay	[PMID: 32485531]
PC-3	IC₅₀	3.51 μg/mL Compound: Resveratrol	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 18586355]
Ramos	IC₅₀	37 μM Compound: RTV	Growth inhibition of human Ramos cells after 2 days by MTT assay Growth inhibition of human Ramos cells after 2 days by MTT assay	[PMID: 28408224]
RAW	IC₅₀	15 μM Compound: 1, Resveratrol	Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells pretreated 30 mins before LPS challenge measured after 20 hrs by Griess reaction method relative to control Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells pretreated 30 mins before LPS challenge measured after 20 hrs by Griess reaction method relative to control	[PMID: 20527891]
RAW	IC₅₀	23.2 μM Compound: 1	Inhibition of LPS-induced iNOS activity in mouse RAW 264.7 cells assessed as inhibition of NO production pretreated with compound for 30 mins before LPS challenge after 24 hrs by Griess reagent method Inhibition of LPS-induced iNOS activity in mouse RAW 264.7 cells assessed as inhibition of NO production pretreated with compound for 30 mins before LPS challenge after 24 hrs by Griess reagent method	[PMID: 23142320]
RAW264.7	IC₅₀	23.2 μM Compound: 1	Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells after 18 hrs Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells after 18 hrs	[PMID: 22386564]
RAW264.7	IC₅₀	24.1 μg/mL Compound: 205	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess reagent based assay	[PMID: 31255927]
RAW264.7	IC₅₀	30.71 μM Compound: 1	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins measured 24 hrs post LPS challenge by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins measured 24 hrs post LPS challenge by Griess method	[PMID: 22386564]
RAW264.7	IC₅₀	30.71 μM Compound: trans-Resveratrol	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins before LPS challenge measured after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins before LPS challenge measured after 24 hrs by Griess method	[PMID: 22115839]
RAW264.7	IC₅₀	44.1 μM Compound: 1a	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFNgamma-induced NO production by measuring NO level preincubated for 2 hrs and followed by LPS/IFNgamma addition and measured after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFNgamma-induced NO production by measuring NO level preincubated for 2 hrs and followed by LPS/IFNgamma addition and measured after 24 hrs by Griess assay	[PMID: 31350127]
SF-268	GI₅₀	4.1 μg/mL Compound: 1a	Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay	[PMID: 19719153]
SF-268	GI₅₀	4.1 μg/mL Compound: E-3	Cytotoxicity against human SF268 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human SF268 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
SK-BR-3	IC₅₀	110.3 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human SK-BR-3 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human SK-BR-3 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32485531]
SK-BR-3	IC₅₀	41.42 μM Compound: RSV, resveratrol	Cytotoxicity against human estrogen receptor negative SKBR3 cells after 72 hrs by MTT assay Cytotoxicity against human estrogen receptor negative SKBR3 cells after 72 hrs by MTT assay	[PMID: 23860590]
SK-MEL	IC₅₀	47.3 μM Compound: 4, (E)-resveratrol	Cytotoxicity against human SK-MEL cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human SK-MEL cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
SK-MEL-2	IC₅₀	14 μM Compound: Resv	Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
SK-N-SH	IC₅₀	40.3 pM Compound: 1, RSV, Resveratrol	Antiproliferative activity against human SK-N-SH cells assessed as cell viability after 48 hrs by SRB assay Antiproliferative activity against human SK-N-SH cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 21851083]
SK-OV-3	IC₅₀	113 μM Compound: 4, (E)-resveratrol	Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
SK-OV-3	IC₅₀	29 μM Compound: Resveratrol	Cytotoxicity against human SKOV3 cells transfected with non-targeted vector assessed as reduction in cell viability incubated for 96 hrs in presence of doxycycline by MTT assay Cytotoxicity against human SKOV3 cells transfected with non-targeted vector assessed as reduction in cell viability incubated for 96 hrs in presence of doxycycline by MTT assay	[PMID: 31514018]
SK-OV-3	IC₅₀	346 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition by LDH release assay Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition by LDH release assay	[PMID: 32485531]
SK-OV-3	IC₅₀	36.3 μM Compound: Resveratrol	Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 31514018]
SK-OV-3	IC₅₀	380 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 24 hrs days by MTT assay Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 24 hrs days by MTT assay	[PMID: 32485531]
SK-OV-3	IC₅₀	39.67 μM Compound: Resveratrol	Cytotoxicity against human SKOV3 cells transfected with shRNA assessed as reduction in cell viability incubated for 96 hrs in presence of doxycycline by MTT assay Cytotoxicity against human SKOV3 cells transfected with shRNA assessed as reduction in cell viability incubated for 96 hrs in presence of doxycycline by MTT assay	[PMID: 31514018]
SK-OV-3	IC₅₀	47.98 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human SK-OV-3 assessed as cell growth inhibition incubated for 72 hrs by MTT assay Anticancer activity against human SK-OV-3 assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32485531]
SK-OV-3	IC₅₀	91.7 μM Compound: Resveratrol	Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 31514018]
SW480	IC₅₀	20 μM Compound: 1	Antiproliferative activity against human SW480 cells assessed as cell viability using propidium iodide staining after 48 hrs Antiproliferative activity against human SW480 cells assessed as cell viability using propidium iodide staining after 48 hrs	[PMID: 20395019]
T47D	IC₅₀	25 μM Compound: Resv	Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
T47D	IC₅₀	59 μM Compound: Resveratrol	Cytotoxicity against human T47D cells after 96 hrs by MTT assay Cytotoxicity against human T47D cells after 96 hrs by MTT assay	[PMID: 26854376]
T47D	IC₅₀	76 μM Compound: Resveratrol	Cytotoxicity against human T47D cells by MTT assay Cytotoxicity against human T47D cells by MTT assay	[PMID: 23273518]
TOV112D	IC₅₀	10.67 μM Compound: Resveratrol	Cytotoxicity against human TOV112D cells transfected with empty vector assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human TOV112D cells transfected with empty vector assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 31514018]
TOV112D	IC₅₀	11 μM Compound: Resveratrol	Cytotoxicity against human TOV112D cells expressing NQO2 assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human TOV112D cells expressing NQO2 assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 31514018]
U-251	IC₅₀	> 50 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human U-251MG cells assessed as cell growth inhibition by CyQuant assay Anticancer activity against human U-251MG cells assessed as cell growth inhibition by CyQuant assay	[PMID: 32485531]
U373-MAGI	CC₅₀	> 400 μM Compound: Res	Cytotoxicity against human U373-MAGI cells by CellTitre-Glo assay Cytotoxicity against human U373-MAGI cells by CellTitre-Glo assay	[PMID: 24120088]
U373-MAGI	EC₅₀	> 75 μM Compound: 1a	Antiviral activity against HIV1 infected in human U373-MAGI cells expressing CXCR4 assessed as inhibition of viral infection preincubated for 2 hrs prior to infection followed by compound wash out measured after 48 hrs by single round replication assay Antiviral activity against HIV1 infected in human U373-MAGI cells expressing CXCR4 assessed as inhibition of viral infection preincubated for 2 hrs prior to infection followed by compound wash out measured after 48 hrs by single round replication assay	[PMID: 23010273]
U373-MAGI	EC₅₀	10 μM Compound: Resveratrol	Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 50 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection measu Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 50 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection measu	[PMID: 27117260]
U373-MAGI	CC₅₀	145 μM Compound: Resveratrol	Increase of 5-Aza-C-mediated cytotoxicity against human U373-MAGI cells at 50 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs measured after 72 hrs by Celltiter-Glo luminescent cell viability assay (Rvb = 387 uM) Increase of 5-Aza-C-mediated cytotoxicity against human U373-MAGI cells at 50 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs measured after 72 hrs by Celltiter-Glo luminescent cell viability assay (Rvb = 387 uM)	[PMID: 27117260]
U373-MAGI	EC₅₀	99.6 μM Compound: Res	Antiviral activity against HIV1 infected in human U373-MAGI cells incubated for 2 hrs prior to viral infection followed by compound washout after 24 hrs measured 72 hrs post-infection by flow cytometry Antiviral activity against HIV1 infected in human U373-MAGI cells incubated for 2 hrs prior to viral infection followed by compound washout after 24 hrs measured 72 hrs post-infection by flow cytometry	[PMID: 24120088]
U-87MG ATCC	IC₅₀	20 μM Compound: Resv	Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
U-937	IC₅₀	17 μM Compound: resveratrol	Cytotoxicity against human U937 cells after 48 hrs by WST1 test Cytotoxicity against human U937 cells after 48 hrs by WST1 test	[PMID: 16252924]
Vero	IC₅₀	73.6 μM Compound: 4, (E)-resveratrol	Cytotoxicity against african green monkey Vero cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against african green monkey Vero cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]

体外研究
(In Vitro)

Resveratrol (trans-Resveratrol; SRT501) 是在多种植物来源中发现的众多多酚化合物之一在绝大多数情况下，Resveratrol 在微摩尔范围内显示出抑制/激活作用，这在药理学上可能是可以实现的，尽管目标在还报道了纳摩尔范围^[1]。
将 MCF-7 细胞接种在添加了 5% FBS 且 Resveratrol 浓度不断增加的 DME-F12 培养基中。对照细胞仅用相同体积的载体 (0.1% 乙醇) 处理。Resveratrol 以剂量依赖性方式抑制 MCF-7 细胞的生长。添加 10 μM Resveratrol 导致 6 天后 82% 的 MCF-7 细胞生长抑制，而在 1 μM 时，仅观察到 10% 的抑制。用 10 μM Resveratrol 处理的细胞的倍增时间为 60 小时，而对照细胞每 30 小时倍增一次。台盼蓝排斥试验表明，在 10 μM 或更低的浓度下，Resveratrol 不会影响细胞活力 (90% 的活细胞)，而在 100 μM 的浓度下，Resveratrol 处理 6 天后只有 50% 的细胞存活。此外，根据 ApoAlert Annexin V 细胞凋亡试剂盒的测定，MCF-7 细胞在与浓度为 10 μM 的 Resveratrol 孵育后不会发生细胞凋亡^[2]。
Resveratrol 通过上调内皮一氧化氮合酶 (eNOS) 的表达、刺激 eNOS 酶活性和阻止 eNOS 解偶联来增加内皮细胞中一氧化氮 (NO) 的产生^[7]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Resveratrol (trans-Resveratrol；SRT501) 以 50 mg/kg (195.5±124.8 mm³；P<0.05) 或 100 mg/kg 处理后，与载体处理动物 (315±94 mm³) 相比，平均肿瘤体积减小(81.7±70.5 mm³；P<0.001)。肿瘤体积与肿瘤质量之间存在良好的相关性^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

228.24

Formula

C₁₄H₁₂O₃

CAS 号

501-36-0

性状

固体

颜色

White to off-white

中文名称

白藜芦醇；虎杖甙元；茋三酚；芪三酚

结构分类

初始来源

微生物

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (438.14 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

Ethanol 中的溶解度 : 50 mg/mL (219.07 mM; 超声助溶)

H₂O 中的溶解度 : < 0.1 mg/mL (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.3814 mL	21.9068 mL	43.8135 mL
5 mM	0.8763 mL	4.3814 mL	8.7627 mL
10 mM	0.4381 mL	2.1907 mL	4.3814 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: 5 mg/mL (21.91 mM); 澄清溶液; 超声助溶

此方案可获得 5 mg/mL的澄清溶液。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 EtOH 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: 5 mg/mL (21.91 mM); 澄清溶液; 超声助溶

此方案可获得 5 mg/mL的澄清溶液。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 EtOH 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% EtOH 90% Corn Oil
Solubility: ≥ 5 mg/mL (21.91 mM); 澄清溶液

此方案可获得 ≥ 5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 EtOH 储备液加到 900 μL 玉米油中，混合均匀。
方案四

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.95 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案五

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.95 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案六

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (10.95 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
方案七

请依序添加每种溶剂： 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 2.5 mg/mL (10.95 mM); 澄清溶液
方案八

请依序添加每种溶剂： 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.95 mM); 澄清溶液

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： 50% PEG300 50% Saline
Solubility: 12.5 mg/mL (54.77 mM); 悬浊液; 超声助溶
方案二

请依序添加每种溶剂： 0.5% CMC-Na/saline water
Solubility: 16.67 mg/mL (73.04 mM); 悬浊液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.94%

选择批次：

Data Sheet (666 KB) SDS (393 KB)

COA (283 KB) HNMR (247 KB) RP-HPLC (253 KB) LCMS (107 KB) 元素分析报告 (206 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Pirola L, et al. Resveratrol: one molecule, many targets. IUBMB Life. 2008 May;60(5):323-32. [Content Brief]

[2]. Lu R, et al. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol. 1999 Jun;179(3):297-304. [Content Brief]

[3]. Lee MH, et al. Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: eukaryotic elongation factor 1A2 as a potential target. Cancer Res. 2009 Sep 15;69(18):7449-58. [Content Brief]

[4]. Du LL, et al. Activation of sirtuin 1 attenuates cerebral ventricular streptozotocin-induced tau hyperphosphorylation and cognitive injuries in rat hippocampi. Age (Dordr). 2014 Apr;36(2):613-23. [Content Brief]

[5]. Smutny T, et al. Resveratrol as an inhibitor of pregnane X receptor (PXR): another lesson in PXR antagonism. J Pharmacol Sci. 2014;126(2):177-8. [Content Brief]

[6]. Eun Nim Kim,et al. Resveratrol, an Nrf2 activator, ameliorates aging-related progressive renal injury. Aging (Albany NY). 2018 Jan; 10(1): 83–99. [Content Brief]

[7]. Huige Li, et al. Resveratrol and Vascular Function. Int J Mol Sci. 2019 Apr 30;20(9):2155. [Content Brief]

Cell Assay ^[2]	To determine the effect of Resveratrol on cell growth, MCF-7 cells are plated in 6-well plates at 10⁵ cells per well in 2 mL of DME-F12 medium supplemented with 5% FBS in the presence or absence of increasing concentrations of Resveratrol. The cell number is measured every 2 days till day 6 with a hemocytometer after detaching the cells with trypsin-EDTA^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[3]	Mice^[3] Female BALB/c (nu/nu) mice, 6 weeks old, are used. PA-1 cells (1×10⁷ in 200 μL PBS) are injected s.c. on the right hind flank. Tumor volume (length×width×depth×0.52) is measured three times a week. After 10 days of implantation, two groups (n=10) are given Resveratrol (dissolved in 5% ethanol and 25% polyethyleneglycol 400 in distilled water) i.p. at a daily dose of 50 or 100 mg/kg body weight for consecutive 4 weeks, whereas the other group receive the vehicle only. Body weights are recorded everyday. Animals are given bromodeoxyuridine (BrdUrd; 10 mg/kg body weight, i.p.) 2 h before sacrifice. Xenograft tumors are weighed and frozen in liquid nitrogen or fixed in 10% formalin and embedded in paraffin. The BrdUrd-labeled cells in paraffin-embedded tissues are detected employing a monoclonal anti-BrdUrd antibody. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Pirola L, et al. Resveratrol: one molecule, many targets. IUBMB Life. 2008 May;60(5):323-32. [Content Brief] [2]. Lu R, et al. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol. 1999 Jun;179(3):297-304. [Content Brief] [3]. Lee MH, et al. Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: eukaryotic elongation factor 1A2 as a potential target. Cancer Res. 2009 Sep 15;69(18):7449-58. [Content Brief] [4]. Du LL, et al. Activation of sirtuin 1 attenuates cerebral ventricular streptozotocin-induced tau hyperphosphorylation and cognitive injuries in rat hippocampi. Age (Dordr). 2014 Apr;36(2):613-23. [Content Brief] [5]. Smutny T, et al. Resveratrol as an inhibitor of pregnane X receptor (PXR): another lesson in PXR antagonism. J Pharmacol Sci. 2014;126(2):177-8. [Content Brief] [6]. Eun Nim Kim,et al. Resveratrol, an Nrf2 activator, ameliorates aging-related progressive renal injury. Aging (Albany NY). 2018 Jan; 10(1): 83–99. [Content Brief] [7]. Huige Li, et al. Resveratrol and Vascular Function. Int J Mol Sci. 2019 Apr 30;20(9):2155. [Content Brief]

Resveratrol 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

Ethanol / DMSO	1 mM	4.3814 mL	21.9068 mL	43.8135 mL	109.5338 mL
	5 mM	0.8763 mL	4.3814 mL	8.7627 mL	21.9068 mL
	10 mM	0.4381 mL	2.1907 mL	4.3814 mL	10.9534 mL
	15 mM	0.2921 mL	1.4605 mL	2.9209 mL	7.3023 mL
	20 mM	0.2191 mL	1.0953 mL	2.1907 mL	5.4767 mL
	25 mM	0.1753 mL	0.8763 mL	1.7525 mL	4.3814 mL
	30 mM	0.1460 mL	0.7302 mL	1.4605 mL	3.6511 mL
	40 mM	0.1095 mL	0.5477 mL	1.0953 mL	2.7383 mL
	50 mM	0.0876 mL	0.4381 mL	0.8763 mL	2.1907 mL
	60 mM	0.0730 mL	0.3651 mL	0.7302 mL	1.8256 mL
	80 mM	0.0548 mL	0.2738 mL	0.5477 mL	1.3692 mL
	100 mM	0.0438 mL	0.2191 mL	0.4381 mL	1.0953 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Resveratrol (Synonyms: 白藜芦醇; trans-Resveratrol; SRT501)

Customer Review

Other Forms of Resveratrol:

MCE 顾客使用本产品发表的 99 篇科研文献

Resveratrol 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 IKK 亚型特异性产品:

查看 Sirtuin 亚型特异性产品:

查看 Antibiotic 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Resveratrol 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Resveratrol (Synonyms: 白藜芦醇; trans-Resveratrol; SRT501)

Customer Review

Other Forms of Resveratrol:

Resveratrol 相关抗体

MCE 顾客使用本产品发表的 99 篇科研文献

Resveratrol 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 IKK 亚型特异性产品:

查看 Sirtuin 亚型特异性产品:

查看 Antibiotic 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Resveratrol 相关抗体:

摩尔计算器

稀释计算器

Resveratrol 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z